|
|
CONTENTS
|
|
|
OVERVIEW
COMMON
COMPLICATIONS DUE TO BONE METASTASES
■
DENOSUMAB
EBRT
FOR ASYMPTOMATIC BONE METASTASES
PAINFUL
BONE METASTASES
■
RADIUM
223
■
BISPHOSPHONATES
■
RANK
LIGAND INHIBITORS
|
|
|
OVERVIEW
|
|
.
|
Fragkoulis
C, Gkialas I, Papadopoulos G, Ntoumas K.
Current
therapeutic options targeting bone metastasis in metastatic
castration resistant prostate cancer.
J
BUON. 2016 Jul-Aug;21(4):787-791.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Saad
F.
Bone-Targeted
Therapy in Prostate Cancer in 2017: Lost Opportunities, Confusion,
and Controversy.
J
Clin Oncol. 2017 Mar 13:JCO2017722793. doi:
10.1200/JCO.2017.72.2793. [Epub ahead of print]
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Traboulsi
SL, Saad F.
The
role of bone-targeted therapies for prostate cancer in 2017.
Curr
Opin Support Palliat Care. 2017 Jul 20. doi:
10.1097/SPC.0000000000000280. [Epub ahead of print]
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Zustovich
F, Pastorelli D.
Therapeutic
management of bone metastasis in prostate cancer: an update.
Expert
Rev Anticancer Ther. 2016 Oct 6:1-13. [Epub ahead of print]
Source
|
Full
text |
Similar
articles
|
|
|
COMMON
COMPLICATIONS DUE TO BONE METASTASES
|
|
|
|
DENOSUMAB
|
|
.
|
Stopeck
AT, Fizazi K, Body JJ, Brown JE, Carducci M, Diel I, Fujiwara Y,
Martín M, Paterson A, Tonkin K, Shore N, Sieber P, Kueppers
F, Karsh L, Yardley D, Wang H, Maniar T, Arellano J, Braun
A.
Safety
of long-term denosumab therapy: results from the open label
extension phase of two phase 3 studies in patients with metastatic
breast and prostate cancer.
Support
Care Cancer. 2015 Sep 3. [Epub ahead of print]
Source
|
Full
text |
Similar
articles
|
|
|
EBRT
FOR ASYMPTOMATIC BONE METASTASES
|
|
.
|
Shulman RM, Meyer JE, Li T, Howell KJ.
External beam
radiation therapy (EBRT) for asymptomatic bone metastases in
patients with solid tumors reduces the risk of skeletal-related
events (SREs).
Ann Palliat Med. 2018 Nov 6. pii:
apm.2018.10.04. doi: 10.21037/apm.2018.10.04. [Epub ahead of
print]
Source
| Full
text |
Similar
articles
|
|
|
PAINFUL
BONE METASTASES
|
|
|
|
RADIUM
223
|
|
.
|
Cox
H, Hames M, Benrashid M.
Radium-223
for the Management of Bone Metastases in Castration-Resistant
Prostate Cancer.
J
Adv Pract Oncol. 2015 Nov-Dec;6(6):565-70.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
El-Amm
J, Aragon-Ching JB.
Radium-223
for the treatment of castration-resistant prostate cancer.
Onco
Targets Ther. 2015 May 18;8:1103-9. doi: 10.2147/OTT.S44291.
eCollection 2015.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Etchebehere
E, Araujo JC, Fox PS, Swanston NM, Macapinlac HA, Rohren
EM.
Prognostic
factors in patients treated with radium-223: the role of skeletal
tumor burden on baseline 18F-fluoride-PET/CT in predicting overall
survival.
J
Nucl Med. 2015 Jun 11. pii: jnumed.115.158626. [Epub ahead of
print]
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Lien
LM, Tvedt B, Heinrich D.
Treatment
of castration-resistant prostate cancer and bone metastases with
radium-223 dichloride.
Int
J Urol Nurs. 2015 Mar;9(1):3-13. Published online 2014 Oct 14.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Nguyen
NC, Shah M, Appleman LJ, Parikh R, Mountz JM.
Radium-223
Therapy for Patients with Metastatic Castrate-Resistant Prostate
Cancer: An Update on Literature with Case Presentation.
Int
J Mol Imaging. 2016;2016:2568031. Epub 2016 Sep 27.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Nilsson
S.
Radionuclide
Therapies in Prostate Cancer: Integrating Radium-223 in the
Treatment of Patients With Metastatic Castration-Resistant
Prostate Cancer.
Curr
Oncol Rep. 2016 Feb;18(2):14. doi: 10.1007/s11912-015-0495-4. Epub
2016 Jan 16.
Source
|
Full
text |
Similar
articles
|
|
|
.
|
Parker
C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD,
Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC,
Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J,
Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R,
Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan
M, Bruland ØS, Sartor O; ALSYMPCA Investigators.
Alpha
emitter radium-223 and survival in metastatic prostate cancer.
N
Engl J Med. 2013 Jul 18;369(3):213-23. doi:
10.1056/NEJMoa1213755.-854
Source
|
Full
text |
Comments
|
Similar
articles
|
|
|
Early
use of abiraterone and radium-223
|
|
.
|
Cursano MC, Santini D, Iuliani M, Paganelli G, De Giorgi U.
Early
use of abiraterone and radium-223 in metastatic prostate cancer.
Lancet Oncol. 2019 May;20(5):e228. doi:
10.1016/S1470-2045(19)30226-8.
Source
| Full
text |
Similar
articles
Comment
on: Smith M et al, Addition of radium-223 to abiraterone acetate
and prednisone or prednisolone in patients with
castration-resistant prostate cancer and bone metastases (ERA
223): a randomised, double-blind, placebo-controlled, phase 3
trial. Lancet Oncol. 2019 Mar;20(3):408-419. doi:
10.1016/S1470-2045(18)30860-X. Epub 2019 Feb 6.
Source
/
Full
text /
Similar
articles
|
|
|
.
|
Hindié E, Morgat C.
Early use of abiraterone and
radium-223 in metastatic prostate cancer.
Lancet Oncol.
2019 May;20(5):e229. doi: 10.1016/S1470-2045(19)30235-9.
Source
| Full
text |
Similar
articles
Comment
on: Smith M et al, Addition of radium-223 to abiraterone acetate
and prednisone or prednisolone in patients with
castration-resistant prostate cancer and bone metastases (ERA
223): a randomised, double-blind, placebo-controlled, phase 3
trial. Lancet Oncol. 2019 Mar;20(3):408-419. doi:
10.1016/S1470-2045(18)30860-X. Epub 2019 Feb 6.
Source
/
Full
text /
Similar
articles
|
|
|
.
|
Smith M, Parker C, Saad F, Miller K, Tombal B, Ng QS, Boegemann M,
Matveev V, Piulats JM, Zucca LE, Karyakin O, Kimura G, Matsubara
N, Nahas WC, Nolè F, Rosenbaum E, Heidenreich A, Kakehi Y,
Zhang A, Krissel H, Teufel M, Shen J, Wagner V, Higano C.
Addition of radium-223 to abiraterone acetate and
prednisone or prednisolone in patients with castration-resistant
prostate cancer and bone metastases (ERA 223): a randomised,
double-blind, placebo-controlled, phase 3 trial.
Lancet
Oncol. 2019 Mar;20(3):408-419. doi: 10.1016/S1470-2045(18)30860-X.
Epub 2019 Feb 6.
Source
| Full
text |
Similar
articles
|
|
|
.
|
Spratt DE.
Combination therapies in prostate cancer:
proceed with caution.
Lancet Oncol. 2019
Mar;20(3):321-323. doi: 10.1016/S1470-2045(18)30929-X. Epub 2019
Feb 6.
Source
| Full
text |
Similar
articles
Comment
on: Smith M et al, Addition of radium-223 to abiraterone acetate
and prednisone or prednisolone in patients with
castration-resistant prostate cancer and bone metastases (ERA
223): a randomised, double-blind, placebo-controlled, phase 3
trial. Lancet Oncol. 2019 Mar;20(3):408-419. doi:
10.1016/S1470-2045(18)30860-X. Epub 2019 Feb 6.
Source
/
Full
text /
Similar
articles
|
|
|
Pain
predicts overall survival
|
|
.
|
Roviello G, Gallicchio R, Bozza G, Rodriquenz MG, Aieta M, Storto
G.
Pain predicts overall survival in men with metastatic
castration-resistant prostate cancer treated with radium-223.
Onco Targets Ther. 2018 Dec 17;12:9-13. doi:
10.2147/OTT.S174206. eCollection 2019.
Source
| Full
text |
Similar
articles
|
|
|
Reversibility
of castration resistance status
|
|
.
|
Ricci M, Frantellizzi V, Bulzonetti N, De Vincentis G.
Reversibility of castration resistance status after
Radium-223 dichloride treatment: Clinical evidence and Review of
the literature.
Int J Radiat Biol. 2018 Dec 17:1-29.
doi: 10.1080/09553002.2019.1558301. [Epub ahead of print]
Source
| Full
text |
Similar
articles
|
|
|
Should
be the primary tumor always treated?
|
|
|
Serretta V, Valerio MR, Costa R, Tripoli V, Murabito A, Princiotta
A, Scalici Gesolfo C, Borsellino N, Verderame F, Gebbia V, Licari
M, Sanfilippo C; members of the GSTU Foundation.
Radium-223
treatment in castration resistant bone metastatic prostate cancer.
Should be the primary tumor always treated?
Urol Oncol.
2019 Dec;37(12):964-969. doi: 10.1016/j.urolonc.2019.08.009. Epub
2019 Oct 7.
Source
.
Similar
articles
|
|
|
|
|
|
|
